MONTANI, MARIA NADIA
 Distribuzione geografica
Continente #
NA - Nord America 1.452
EU - Europa 1.129
AS - Asia 806
AF - Africa 9
OC - Oceania 5
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 3.406
Nazione #
US - Stati Uniti d'America 1.446
CN - Cina 777
IE - Irlanda 314
UA - Ucraina 242
FI - Finlandia 164
DE - Germania 124
IT - Italia 87
SE - Svezia 67
GB - Regno Unito 60
FR - Francia 23
BE - Belgio 15
IR - Iran 15
PL - Polonia 14
MU - Mauritius 8
CA - Canada 6
IN - India 6
RU - Federazione Russa 6
AU - Australia 3
CZ - Repubblica Ceca 3
ID - Indonesia 3
NL - Olanda 3
RO - Romania 3
BR - Brasile 2
EU - Europa 2
GR - Grecia 2
NZ - Nuova Zelanda 2
TR - Turchia 2
BD - Bangladesh 1
CH - Svizzera 1
EG - Egitto 1
PE - Perù 1
PH - Filippine 1
SM - San Marino 1
TH - Thailandia 1
Totale 3.406
Città #
Chandler 322
Dublin 312
Jacksonville 297
Nanjing 231
Ashburn 86
Nanchang 86
Hebei 73
Changsha 70
Ann Arbor 64
Lawrence 64
Princeton 64
Beijing 61
Jiaxing 58
Shenyang 58
Wilmington 53
Boardman 48
Medford 45
Tianjin 41
Helsinki 39
Hangzhou 30
Woodbridge 22
Des Moines 19
Brussels 15
Verona 15
Radomsko 14
Kunming 12
Milan 12
Seattle 12
Jinan 9
Norwalk 9
Shanghai 9
Fairfield 8
Leawood 7
Zanjan 7
Auburn Hills 6
San Francisco 6
Ningbo 5
Taizhou 5
Chicago 4
Fuzhou 4
Rome 4
Toronto 4
Washington 4
Zhengzhou 4
Ardabil 3
Ceska 3
Lanzhou 3
Los Angeles 3
New York 3
Sydney 3
Changchun 2
Dearborn 2
Falls Church 2
Florence 2
Genova 2
Guangzhou 2
Houston 2
Las Vegas 2
Lecco 2
Mumbai 2
Napoli 2
Novokuznetsk 2
Poggibonsi 2
Pontedassio 2
Sacramento 2
Shaoxing 2
Alexandria 1
Andover 1
Athens 1
Auckland 1
Bangkok 1
Belfast 1
Bellinzona 1
Berlin 1
Borås 1
Cairo 1
Carcare 1
Cork 1
Dhaka 1
Gostar 1
Gravedona 1
Henderson 1
Huizen 1
Impruneta 1
Jakarta 1
Kingston 1
Lima 1
London 1
Manila 1
Media 1
Miane 1
Monmouth Junction 1
Mountain View 1
Palermo 1
Piacenza 1
Pinehaven 1
Piscataway 1
Polizzi Generosa 1
Pune 1
Redwood City 1
Totale 2.402
Nome #
Screening dei difetti dell'emostasi con Platelet Function Analyzer (PFA-100) in donne con meno-metrorragia 112
L'artropatia e l'emartro ricorrente nelle coagulopatie congenite: l'influenza del trattamento. 86
Haemostatic variables, serum lipid abnormalities and vascular complications in diabetes mellitus: a 5 year follow-up study. 82
Activation of the haemostatic process in patients with unruptured aortic aneurysm before and after surgical repair 80
Caratteristiche dell'emartro ed evoluzione in artropatia nelle coagulopatie congenite: osservazione su 145 casi afferenti al centro emofilia di Pavia 78
Screening for congenital bleeding disorders with platelet function analyzer (PFA-100) in women with menorrhagia 77
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 77
Atherosclerosis, vascular damage, thrombotic risk factors and congenital bleeding disorders 73
Acquired von Willebrand syndrome and monoclonal gammopathy: clinical characterization and recovery to infusion of VWF-containing concentrates 68
Effect of low molecular weight heparin on some markers of platelet and thrombin activation in patients with inflammatory bowel diseasesnresponsive to the standard therapy 68
L'artropatia e l'emartro nelle coagulopatie congenite: l'influenza del trattamento 65
Bleeding disorders in children with reccurent tonsillitis and prolonged aPTT 64
Clotting alterations in primary systemic amyloidosis. 64
PLASMA PROTEIN-Z LEVELS AND HEMOSTASIS IN PATIENTS ON DICUMAROL TREATMENT AND IN PATIENTS WITH BLEEDING TENDENCY OF UNKNOWN ORIGIN 62
Platelet function after 'in vivo' and 'in vitro' treatment with thrombolytic agents. 62
STUDY OF THREE PATIENTS WITH MONOCLONAL GAMMAPATHIES AND "LUPUS-LIKE" ANTICOAGULANTS. 61
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 61
Vascular damage, prothrombotic risk factor and trombosis in patients with inherited bleeding disorders 60
Factor V Leiden mutation and risk of thrombotic complications in children treated for lynphoprolipherative diseases 60
Efficacy and safety of high doses of FEIBA for major surgery in a patient with haemophilia A and high titre inhibitor 59
Patterns of bleeding,comorbidities, and clinical courses in acquired hemophilia A (AHA) and in acquired von Willebrand disease (AVWD): Experience from a single hemophiliaentre in Pavia 59
High prevalence of fibrin formation defects in women with menorrhagia and congenital bleeding disorders 58
Long-term evaluation of synovectomy and synoviorthesis on the evolution of joint damage: what's happened after 30 years of follow up? 58
Malattia di von Willebrand acquisita in 2 pazienti con malattia infiammatoria cronica intestinale 58
Cardiovascular disease, hyperhomocysteinemia and atherothrombotic risk factors in psoriatic patients 57
Defective anticoagulation system in patients with previous myocardial infarction and residual angina 56
The behaviour of physiologic and acquired anticoagulants in patients with hyperhomocysteinemia and thrombotic complications 56
Hyperhomocysteinemia and FV ARG 506 GLN in 81 consecutive patients with thrombosis. 56
Treatment of bleeding episodes in acquired haemophilia with activated prothrombin complex concentrate: what is the optimal therapy? 55
Homocysteine plasma levels and vascular damage in congenital clotting factor deficiencies 55
Influenza del polimorfismo C677T del gene della MTHFR sui livelli di omocisteina plasmatici e sul rischio trombotico 54
Prevalenza di trombosi arteriose e venose in presenza delle mutazioni G20210A del gene della protrombina e R506Q del gene del FV (Leiden) 54
Performance in sports of children and adolescents with hereditary bleeding disorders 53
Thrombotic markers and mitral valve prolapse in migraine with and without aura at childhood onset 52
Efficacy and safety of factor VIII inhibitor by-passing activity (FEIBA) in high thrombotic risk patients with acquired haemophilia (AH) Efficacy and safety of factor VIII inhibitor by-passing activity (FEIBA) in high thrombotic risk patients with acquired haemophilia (AH) 52
Activation of the haemostatic process in patients with unruptured aortic aneurysm before and in the first week after surgical repair. 52
Imbalance of oxidant and antioxidant mechanism in ischaemic heart diseases 51
Von Willebrand factor/factor VIII behaviour and haemorrhagic manifestations in patients with neurofibromatosis type I 49
Expression of dipeptidylaminopeptidase IV/CD26 in peripheral blood lymphocytes of hemophilic subjects. 49
Purpura Fulminans As Clinical Manifestation of Atypical Sle With Antiphospholipid Antibodies - A Case-report 48
Prolonged aPTT occasionally detected in children before adenotonsillectomy and bleeding disorders 48
Impaired expression of dipeptidylaminopeptidase IV (DAPN)/CD26 in lymphocytes of hemophiliacs 47
Haemarthroses and arthropathy in mild/moderate haemophilia: data collected from a single Haemophilia Centre, Pavia, Italy 47
Normalization of homocysteine plasma levels improves the physiological anticoagulation in patients with thromboembolic diseases 46
THROMBOPHILIC SCREENING IN TURNER SYNDROME. 45
Risk of venous thrombosis (VT) and hormonal replacement therapy (HRT) in Turner sindrome 45
Platelet function after in vivo and in vitro treatment with thrombolytic agents 45
Bleeding tendency in type I neurofibromatosis is related to von Willebrand factor abnormalities 45
Clotting alterations in primary systemic amyloidosis 43
Treatment and progression of liver damage in HCV+ haemophiliacs: over 15 years follow up 42
Bleeding tendency of unknown origin and protein Z levels. 42
Risk factors of thrombosis in poorly controlled inflammatory bowel diseases: benefecial effect of LMW heparin as adjuvant therapy 40
Long-term follow up in Acquired Hemophilia A: clinical courses and outcomes observed in a single Hemophilia Centre 39
Modalità di diagnosi e caratteristiche cliniche della M di von Willebrand acquisita 39
Mitral valve prolapse and abnormalities of haemostasis in children and adolescents with migraine with aura and other idiopathic headaches: a pilot study. 38
Thromboembolic disease and thrombotic risk factors: The effect of treating Hìhyperhomocysteinemia on physiological anticoagulation 37
Activated prothrombin complex concentrate (FEIBA®) for the treatment and prevention of bleeding in patients with acquired haemophilia: A sequential study 37
Two years prophylaxis with FEIBA and inhibitors levels in a high responder haemophilic patient 35
Ruolo patogenetico delle alterazioni emocoagulative nell'insorgenza di s poliabortiva e di patologie ostetriche 33
Mitral valve prolapse and abnormalities of haemostasis in children and adolescents with migraine with aura and other idiopathic headaches: a pilot study. 32
Menometrorrhagia in adolescents: is it the first expression of congenital defects of hemostasis 31
Haemostasis and low molecular weight heparin (LMWH) therapy in chronic inflammatory bowel diseases (IBD) not responsive to conventional therapy. 28
Study of three patients with monoclonal gammopathies and 'lupus-like' anticoagulants 27
Homocysteine and liver steatosis in HCV infected haemophiliacs 24
Totale 3.436
Categoria #
all - tutte 10.549
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.549


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 0 0 0 0 0 0 0 1 20
2019/2020936 250 385 6 46 1 53 20 53 5 74 40 3
2020/2021436 60 43 12 48 1 59 6 63 9 65 57 13
2021/2022311 10 0 7 6 2 3 14 13 24 13 39 180
2022/2023958 110 65 3 86 110 115 0 48 367 12 29 13
2023/2024243 44 36 14 25 40 54 1 19 4 3 3 0
Totale 3.436